骨髓瘤对蛋白酶体抑制剂及其他靶向治疗的耐药机制
本综述描述了骨髓瘤主要新型治疗类别(蛋白酶体抑制剂、免疫调节剂、单克隆抗体、组蛋白去乙酰化酶抑制剂、核输出抑制剂等),概述了各类别的主要临床试验,并讨论了已知的耐药机制;文章指出耐药机制在蛋白酶体抑制剂(尤其硼替佐米)研究最充分,但类别效应并非普遍适用于所有同类药物,同类药物间在疗效、毒性和耐药机制上存在差异。
要点
- 骨髓瘤新型治疗包括蛋白酶体抑制剂、免疫调节剂、单克隆抗体、组蛋白去乙酰化酶抑制剂和核输出抑制剂等。
- 耐药机制在蛋白酶体抑制剂(尤其硼替佐米)研究最充分,但类别效应并非普遍适用于所有同类药物。
- 免疫调节剂共同靶点为cereblon,耐药模式与cereblon表达相关;单克隆抗体因靶向独特细胞表面抗原,同类药物间疗效和耐药模式常存在差异。
核心结论
- 骨髓瘤新型治疗快速发展,同时出现新的耐药机制,许多机制仍未明确,尤其对较新开发的药物。
研究设计与样本
- 综述,描述骨髓瘤主要新型治疗类别,重点介绍各类别的主要临床试验并讨论已知耐药机制。
主要发现
- 蛋白酶体抑制剂、免疫调节剂和单克隆抗体是靶向骨髓瘤最知名和研究最充分的新型药物类别,组蛋白去乙酰化酶抑制剂、核输出抑制剂等也在积极研究中。
- 耐药机制在蛋白酶体抑制剂(尤其硼替佐米)研究最充分,但类别效应并非普遍适用于所有同类药物,同类药物间在疗效、毒性和耐药机制上存在差异。
- 免疫调节剂共同细胞靶点为cereblon,耐药模式与cereblon表达相关;单克隆抗体靶向独特细胞表面抗原,同类药物间临床疗效和耐药模式常存在差异。
局限性
- 许多耐药机制仍未明确,尤其对较新开发的药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The number of novel therapies for the treatment of myeloma is rapidly increasing, as are the clinical trials evaluating them in combination with other novel and established therapies. Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies are the most well known and studied classes of novel agents targeting myeloma, with histone deacetylase inhibitors, nuclear export inhibitors and several other approaches also being actively investigated. However, in parallel with the development and clinical use of these novel myeloma therapies is the emergence of novel mechanisms of resistance, many of which remain elusive, particularly for more recently developed agents. Whilst resistance mechanisms have been best studied for proteasome inhibitors, particularly bortezomib, class effects do not universally apply to all class members, and within-class differences in efficacy, toxicity and resistance mechanisms have been observed. Although immunomodulatory agents share the common cellular target cereblon and thus resistance patterns relate to cereblon expression, the unique cell surface antigens to which monoclonal antibodies are directed means these agents frequently exhibit unique within-class differences in clinical efficacy and resistance patterns. This review describes the major classes of novel therapies for myeloma, highlights the major clinical trials within each class and discusses known resistance mechanisms.
引用
- Wallington-Beddoe CT, Sobieraj-Teague M, Kuss BJ, et al. Resistance to proteasome inhibitors and other targeted therapies in myeloma. Br J Haematol. 2018. PMID: 29676460. doi:10.1111/bjh.15210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。